Vicenin 2 (Synonyms: Vicenin II, Violantin) |
| Catalog No.GC37902 |
Vicenin 2 es un inhibidor de la enzima convertidora de angiotensina (ACE) (IC50=43.83 μM) de las partes aéreas de Desmodium styracifolium.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 23666-13-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Vicenin 2 is an orally active angiotensin-converting enzyme (ACE) inhibitor with the IC50 value of 43.83 ± 3.01μM[1]. Vicenin 2 has anti-inflammatory and antioxidant properties which make it potential applications in various fields, including skin health and cancer therapy.
In vitro, Vicenin 2 (6.25–400μM) incubated human dermal fibroblast (HDF) cell for 24h. Vicenin 2 treatment on HDF cells enhanced cell proliferation in a dose-dependent up to 50μM, but the higher concentrations inhibited proliferation. Low concentrations of Vicenin 2 (12.5 and 25μM) have significantly induced the cell migration and wound closure, while higher concentrations (50 and 100µM) reduced these effects. In addition, treatment with 100μM of Vicenin 2 on HDF significantly increased the expression of inflammatory cytokines and higher expression for inflammatory mediators (NF-κB, iNOS, and COX-2) and healing growth factors (VEGF and TGF-β) proteins[2]. Vicenin 2 (40μM) incubation for 24 hours can restore the antioxidant defense of human gastric epithelial cells (GES-1) by modulating key signaling pathways (PI3K/AKT and MAPK) and upregulating Nrf2 expression, effectively protecting them from cytotoxicity, oxidative stress, DNA damage, and inflammation induced by Helicobacter pylori. These findings suggest that Vicenin 2 could serve as a potential therapeutic agent for preventing H. pylori-induced gastric carcinogenesis[3]. NCI-H23 cells were treated with 10–100µM of Vicenin 2 for 24h. There was a gradual reduction in the percent surviving cells from 60µM to 100µM. NCI-H23 cells treated with radiation exposure with and without 80µM Vicenin 2 suggested that there was greater reduction in percent cell survival with Vicenin 2 treatment. Vicenin 2 showed a potent radiosensitizing property while also showing chemotherapeutic property against Non-small cell lung cancer (NSCLC) cell line NCI-H23[4].
In vivo,Vicenin 2 (50mg/kg/day) administered orally via oral gavage tube into dextran sulfate sodium-induced colitis mice model for 7 days exerted therapeutic effects by the inhibition of pro-inflammatory mediators (iNOS and COX-2) and suppression of specific inflammatory markers expression[5]. In a study on ovariectomy (OVX)-induced osteoporosis rat models, Vicenin 2 orally administered at doses of 5mg/kg/day or 10mg/kg/day for 12 consecutive weeks significantly improved body mass, uterus index, lipid profiles, and inflammatory markers. Vicenin 2 also reduced bone turnover markers and increased serum calcium levels in the OVX rats. These results suggested that Vicenin 2 could be an excellent candidate to treat and manage bone related disease or disorders[6]. The administration of Vicenin 2 (23.8µg/mouse) into LPS-induced lethal endotoxemia model given twice at 12 and 50 hours post-LPS injection, significantly increased survival rates, reduced endothelial cell protein C receptor shedding, decreased pro-inflammatory cytokine expression, protected vascular barrier integrity, and inhibited leukocyte migration. These findings suggest that Vicenin 2 could serve as a potential therapeutic agent for treating severe vascular inflammatory diseases [7].
References:
[1] Zhang YQ, et al. Bioassay-guided preparative separation of angiotensin-converting enzyme inhibitory C-flavone glycosides from Desmodium styracifolium by recycling complexation high-speed counter-current chromatography. J Pharm Biomed Anal. 2015 Jan;102:276-81.
[2] Tan W S, Arulselvan P, Ng S F, et al. Healing Effect of Vicenin-2 (Vicenin-2) on Human Dermal Fibroblast (HDF) and Development Vicenin-2 Hydrocolloid Film Based on Alginate as Potential Wound Dressing. Biomed Res Int. 2020 Apr 23:2020:4730858.
[3] Zhang Y F, Sun J, Dong Y, et al. Vicenin-2 inhibits the Helicobacterium pylori infection associated gastric carcinogenic events through modulation of PI3K/AKT and Nrf2 signaling in GES-1 cells. J Biochem Mol Toxicol. 2021 Mar;35(3):e22680.
[4] Baruah T J, Sharan R N, Kma L. Vicenin-2: a potential radiosensitizer of non-small cell lung cancer cells. Mol Biol Rep. 2018 Oct;45(5):1219-1225.
[5] Yin Y T, Ye L, Niu Z B, Fang W H.Anti-inflammatory effects of Vicenin-2 on dextran sulfate sodium-induced colitis in mice. Drug Dev Res. 2019 Aug;80(5):546-555.
[6] Zhang Z P, Zhao Q P, Liu T J,et al. Effect of Vicenin-2 on ovariectomy-induced osteoporosis in rats. Biomed Pharmacother. 2020 Sep:129:110474.
[7] Kang H J, Ku S K, Jung B K, BaeJ S. Anti-inflammatory effects of vicenin-2 and scolymoside in vitro and in vivo. Inflamm Res. 2015 Dec;64(12):1005-21.
| Cell experiment [1]: | |
Cell lines | Non-small cell lung cancer cell line NCI-H23 |
Preparation Method | NCI-H23 cells were treated with 10–100µM of Vicenin 2 for 24h. |
Reaction Conditions | 10-100µM; 24h |
Applications | Between the doses of 10–50µM, there was no corresponding decrease in cell survival with increase in Vicenin 2 dose. However, from 60µM onwards to 100µM, there was a gradual reduction in the percent surviving cells.The results suggest that Vicenin 2 is cytotoxic to cancer cells. |
| Animal experiment [2]: | |
Animal models | female Wistar rats |
| Preparation Method | Rats underwent either bilateral laparotomy alone or bilateral ovariectomy (OVX group) via midline dorsal incision. After 4 weeks of recovery period all the OVX rats were divided into 3 groups as OVX alone, OVX rats orally administrated (by oral gavage) with 5mg/kg/day of Vicenin 2 or 10mg/kg/day of Vicenin 2 for 12 successive weeks. |
Dosage form | 5 and 10mg/kg; orally administrated; daily for 12 weeks |
Applications | Vicenin 2 mitigated osteoporosis in ovariectomized rats by improving body mass, uterus index, lipid profiles, inflammatory markers, bone turnover markers and amplifying the presence of calcium in the OVX rat serum. |
References: | |
| Cas No. | 23666-13-9 | SDF | |
| Sinónimos | Vicenin II, Violantin | ||
| Canonical SMILES | OC1=C([C@@H]([C@@H]([C@@H](O)[C@@H]2O)O)O[C@@H]2CO)C(O)=C3C(OC(C4=CC=C(O)C=C4)=CC3=O)=C1[C@@H]([C@@H]([C@@H](O)[C@@H]5O)O)O[C@@H]5CO | ||
| Formula | C27H30O15 | M.Wt | 594.52 |
| Solubility | DMSO : 33.33 mg/mL (56.06 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble) | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.682 mL | 8.4101 mL | 16.8203 mL |
| 5 mM | 0.3364 mL | 1.682 mL | 3.3641 mL |
| 10 mM | 0.1682 mL | 0.841 mL | 1.682 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *